Wednesday, February 12, 2014
Biondvax Pharmaceuticals Ltd., of Nes Ziona, Israel, received approval from Hong Kong’s patent office to register its patent covering Multimeric Multiepitopes for the company’s universal flu vaccine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.